General
Preferred name
Nitroarginine
Synonyms
N (g)-NITRO-L-ARGININE ()
NG-Nitro-L-arginine ()
N'-Nitro-L-arginine ()
L-nitro-Arginine ()
NG-nitro-arginine ()
N¦Ø-nitro-L-arginine ()
L-NNA ()
Nω-nitro-L-arginine ()
L-NOARG ()
L-NG-Nitroarginine ()
NSC-53662 ()
P&D ID
PD001370
CAS
2149-70-4
1015842-89-3
Tags
available
drug candidate
Drug Status
investigational
Max Phase
1.0
Drug indication
Neoplasm
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
L-NNA is an arginine analogue used as a biochemical tool in the study of nitric oxide and its biological effects. L-NNA inhibits the endothelial and neuronal isoforms of nitric oxide synthase (NOS), eNOS and nNOS respectively more potently than the inducible iNOS .
Selective nNOS inhibitors are being pursued for their potential to treat neurological disorders caused by excessive production of nitric oxide. (GtoPdb)
Selective nNOS inhibitors are being pursued for their potential to treat neurological disorders caused by excessive production of nitric oxide. (GtoPdb)
DESCRIPTION
NG-nitro-L-arginine (N¦Ø-nitro-L-arginine) is a NO Synthase inhibitor, with Kis of 0.61 ¦ÌM (nNOS), 4.28 ¦ÌM (iNOS), 0.72 ¦ÌM (eNOS) respectively. NG-nitro-L-arginine inhibits endothelium-derived relaxing factor (EDRF) formation and release. NG-nitro-L-arginine inhibits portal-systemic shunting in portal-hypertensive rats, and increases blood pressure[1][2][3][4].
PRICE
29
DESCRIPTION
L-NNA is a competitive inhibitor of nitric oxide synthase (NOS) with selectivity for the neuronal and endothelial isoforms of the enzyme. It inhibits human neuronal nitric oxide synthase with Ki = 10 nM.
(Enamine Bioactive Compounds)
DESCRIPTION
Potent nitric oxide synthase inhibitor
(LOPAC library)
DESCRIPTION
Nitroarginine (N'-Nitro-L-arginine) is a competitive inhibitor of nitric oxide synthase which causes the selective reduction of blood flow to tumor cells[1].
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
1
Compound Sets
16
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
109
Molecular Weight
219.1
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
5
Rotatable Bonds
6
Ring Count
0
Aromatic Ring Count
0
cLogP
-1.52
TPSA
154.37
Fraction CSP3
0.67
Chiral centers
1.0
Largest ring
0.0
QED
0.12
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
NOS
Target
nitric oxide
NOS1, NOS2, NOS3
NO Synthase
Member status
member
MOA
Nitric Oxide Synthase Inhibitors
nitric oxide synthase inhibitor
Pathway
Immunology/Inflammation
Source data

